Discovery Activities
Translational focus from the start to bring the right drug to the right patient
At Oncodesign, we strongly believe in Platform Based Drug Discovery. The combination of four complementary research platforms creates a continuum from compound conception to clinical application. The early integration of biomarker discovery and multi-modality imaging allows to position the resulting compounds towards the patients that need them most.
Our
Discovery Projects are
based on the Nanocyclix®
technology
and compounds. This medicinal chemistry platform provides
access to
biologically active macrocyclic small molecules with unique properties.
The Nanokinib®
library contains hundreds of diversified and novel kinase
inhibitors that provide highly potent and selective leads for both well
established and unexplored kinases, with good overall drug-like
properties. In addition, the platform approach allows for accelerated
and resource-efficient optimisation.
Oncodesign
proposes shared risk Discovery
Programs starting from its internal pipeline of programs, or applies its proprietary Nanocyclix® technology on its partner's leads and/or targets.
Oncodesign proposes fully integrated Therapeutic & Biomarker development
READ MORE